Solara Active Pharma Sciences Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/y74wyx6mflidxmm9h9v0nts6.pdf

Key Takeaways


The Turnaround: Governance Over Market Tailwinds

Arun Kumar: "I just think that we have reset our business from being all over the place to be very focused on what we want to achieve. And the numbers that you're seeing is a reflection of a course correction and not necessarily the market dynamics."

Vizag Facility: The FY26 Growth Engine

Arun Kumar: "We have fully sold for capacity and Vizag in fact has been retrofitted to add more capacities around that line of items. It's a very complex chemistry, not many players out of India."

Ibuprofen & API Pricing: Hitting the Floor

Arun Kumar: "We work in an industry where we can't predict what happens next week. So, you're asking me to answer an impossible question."

CRAMS & New Bets: Early Days

Arun Kumar: "Well, I think so it's -- see, everybody talks about peptides. It's more fashionable than anything else. Everybody is in it."

Balance Sheet & Tax: Repair Underway


Guidance & Commitments

CommitmentSpecificsTimeline
Q4 FY25 exit run rateINR400 crores revenueQ4 FY25
Vizag plant restartBack on stream, zero under-recoveries for the full yearQ1 FY26
Debt-to-EBITDABelow 1.5xIf guidance is met (implied FY25)
Net cash positionVery strong position or very close to net cashFY27
CRAMS revenue share10% of salesFY26
DMF filingsFour to five new filingsOver the next two years
Tax rate0%FY25 and FY26; changes from FY27

Key Metrics

MetricQ2 FY25
Revenue₹347-odd cr, Q4 exit run rate guided to ₹400 cr
Gross margin50.5%, historical high, up 620 bps YoY and approximately flat QoQ
Gross margin (Q1 FY25)44.5%, sequential jump to 50.5% driven by cost containment and product mix
Operating expenditure₹113 cr, down from ₹130 cr in Q4 FY24 and a base of approx ₹135 cr
Net debtBelow ₹500 cr, adjusted for uncalled rights issue money of ₹222 cr
Debt-to-EBITDAUnder 2x, expected to improve to less than 1.5x if guidance is hit
Regulated market share76% of revenue, stable sequentially
Ibuprofen group revenue share~25% of global revenues, the largest product group
CRAMS annualized revenueLess than ₹100 cr, on track for ~7-8% of guided ₹1,500 cr revenue
CRAMS revenue target (FY26)10% of sales
Vizag capacity mothballed33-35% of total capacities, plant being retrofitted to multipurpose including HPAPI
Vizag gross block~₹500 cr, net block ~₹250 cr, with additional capex plan of ~₹100 cr
Vizag asset turn target1x to 1.2x, expected to take at least two years from restart
Vizag restart timelineQ1 FY26, with zero under-recoveries expected in FY26
New DMF filings planned4 to 5 over the next two years, focus on commercializing existing portfolio